282 related articles for article (PubMed ID: 27053529)
1. How I treat refractory immune thrombocytopenia.
Cuker A; Neunert CE
Blood; 2016 Sep; 128(12):1547-54. PubMed ID: 27053529
[TBL] [Abstract][Full Text] [Related]
2. Current therapies in primary immune thrombocytopenia.
Pels SG
Semin Thromb Hemost; 2011 Sep; 37(6):621-30. PubMed ID: 22102265
[TBL] [Abstract][Full Text] [Related]
3. Current approaches for the diagnosis and management of immune thrombocytopenia.
Gafter-Gvili A
Eur J Intern Med; 2023 Feb; 108():18-24. PubMed ID: 36424271
[TBL] [Abstract][Full Text] [Related]
4. Autoimmune thrombocytopenia: Current treatment options in adults with a focus on novel drugs.
Witkowski M; Witkowska M; Robak T
Eur J Haematol; 2019 Dec; 103(6):531-541. PubMed ID: 31449692
[TBL] [Abstract][Full Text] [Related]
5. Retrospective analysis of rituximab therapy and splenectomy in childhood chronic and refractory immune thrombocytopenic purpura.
Ay Y; Karapinar TH; Oymak Y; Toret E; Demirag B; Ince D; Ozcan E; Moueminoglou N; Koker SA; Vergin C
Blood Coagul Fibrinolysis; 2016 Jun; 27(4):431-5. PubMed ID: 26656905
[TBL] [Abstract][Full Text] [Related]
6. [Treatment of ITP].
Yokoyama K
Rinsho Ketsueki; 2021; 62(8):1229-1235. PubMed ID: 34497211
[TBL] [Abstract][Full Text] [Related]
7. All-trans retinoic acid plus low-dose rituximab vs low-dose rituximab in corticosteroid-resistant or relapsed ITP.
Wu YJ; Liu H; Zeng QZ; Liu Y; Wang JW; Wang WS; Jia-Feng ; Zhou HB; Huang QS; He Y; Fu HX; Zhu XL; Jiang Q; Jiang H; Chang YJ; Xu LP; Huang XJ; Zhang XH
Blood; 2022 Jan; 139(3):333-342. PubMed ID: 34665865
[TBL] [Abstract][Full Text] [Related]
8. Is splenectomy necessary for immune thrombocytopenic purpura? The role of rituximab in patients with corticosteroid resistance in a single-center experience.
Zhang C; Liu HF; Chen XH; Gao L; Gao L; Liu Y; Kong PY; Sun AH; Zhang X
Clin Ther; 2014 Mar; 36(3):385-8. PubMed ID: 24594069
[TBL] [Abstract][Full Text] [Related]
9. Rituximab as second-line treatment for adult immune thrombocytopenia (the RITP trial): a multicentre, randomised, double-blind, placebo-controlled trial.
Ghanima W; Khelif A; Waage A; Michel M; Tjønnfjord GE; Romdhan NB; Kahrs J; Darne B; Holme PA;
Lancet; 2015 Apr; 385(9978):1653-61. PubMed ID: 25662413
[TBL] [Abstract][Full Text] [Related]
10. Diagnosis and management of primary immune thrombocytopenia in adults.
Ejaz A; Radia D
Br J Hosp Med (Lond); 2019 Apr; 80(4):C54-C57. PubMed ID: 30951423
[No Abstract] [Full Text] [Related]
11. Childhood immune thrombocytopenia: role of rituximab, recombinant thrombopoietin, and other new therapeutics.
Journeycake JM
Hematology Am Soc Hematol Educ Program; 2012; 2012():444-9. PubMed ID: 23233617
[TBL] [Abstract][Full Text] [Related]
12. Successful treatment of refractory secondary immune thrombocytopenia (antiphospholipid antibody syndrome-associated) with the combination of rituximab and romiplostim at the cost of severe bone pain: A case report and review of literature.
Yassa G; Shakir AR; Jagarlamudi K; Yassa AE
J Oncol Pharm Pract; 2021 Jan; 27(1):253-257. PubMed ID: 32611269
[TBL] [Abstract][Full Text] [Related]
13. Thrombopoietin receptor agonists for preparing adult patients with immune thrombocytopenia to splenectomy: results of a retrospective, observational GIMEMA study.
Zaja F; Barcellini W; Cantoni S; Carpenedo M; Caparrotti G; Carrai V; Di Renzo N; Santoro C; Di Nicola M; Veneri D; Simonetti F; Liberati AM; Ferla V; Paoloni F; Crea E; Volpetti S; Tuniz E; Fanin R
Am J Hematol; 2016 May; 91(5):E293-5. PubMed ID: 26910388
[TBL] [Abstract][Full Text] [Related]
14. [Diagnostic approach and treatment of immune thrombocytopenia in adults].
Kolonić SO; Patekar MB; Milunović V
Acta Med Croatica; 2013 Mar; 67(1):3-11. PubMed ID: 24279250
[TBL] [Abstract][Full Text] [Related]
15. New treatments for primary immune thrombocytopenia.
Mingot-Castellano ME
Blood Coagul Fibrinolysis; 2022 Jan; 33(Suppl 1):S8-S11. PubMed ID: 34654012
[TBL] [Abstract][Full Text] [Related]
16. [Reference guide for the treatment of adult idiopathic thrombocytopenic purpura].
Kashiwagi H
Rinsho Ketsueki; 2020; 61(9):1325-1330. PubMed ID: 33162532
[TBL] [Abstract][Full Text] [Related]
17. Sequence of treatments for adults with primary immune thrombocytopenia.
George JN
Am J Hematol; 2012 May; 87 Suppl 1():S12-5. PubMed ID: 22389032
[TBL] [Abstract][Full Text] [Related]
18. New options after first-line therapy for chronic immune thrombocytopenic purpura.
Burzynski J
Am J Health Syst Pharm; 2009 Jan; 66(2 Suppl 2):S11-21. PubMed ID: 19139486
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of adding rituximab to splenectomy and romiplostim for treating steroid-resistant idiopathic thrombocytopenic purpura in adults.
Kikuchi K; Miyakawa Y; Ikeda S; Sato Y; Takebayashi T
BMC Health Serv Res; 2015 Jan; 15():2. PubMed ID: 25609557
[TBL] [Abstract][Full Text] [Related]
20. [Treatment outcome of immune thrombocytopenia].
Iványi JL; Marton E; Plander M
Orv Hetil; 2012 Oct; 153(41):1613-21. PubMed ID: 23045311
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
